June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances. The technology sector, as tracked by the Technology Select Sector SPDR Fund (NYSE:XLK), led the 11 S&P 500 sectors in performance last month, surging 7.7% and achieving its strongest monthly gain this year. In stark contrast, utilities lagged, with the Utilities Select Sector SPDR Fund (NYSE:XLU) dropping 6.3%, marking the worst month since September 2023. Top Performing Industry ETFs In June The iShares Expanded Tech-Software Sector ETF (NYSE:IGV) rallied 11.3% last month, topping

Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple witching” day, with over $5.1 trillion of notional options exposure expiring, surpassing the previous record set in December 2023. Chipmakers continue to struggle in the aftermath of Thursday’s sell-off, suggesting that while the wave of profit-taking is easing, there is little sign of new buyers stepping in at these levels. Nvidia Corp. is down 1.6%, poised to break an eight-week winning streak. The sector benchmark, the iShares Semiconductor ETF (NYSE:SOXX), is witnessing its worst two-day performance since May 1. The major indices and sectors remained flat,

As April comes to a close, it’s time to compile the rankings for the top-performing sector and industry exchange-traded funds of the month. Taking a broader look at the stock market, the S&P 500 Index, represented by the SPDR S&P 500 ETF Trust (NYSE:SPY), finished April on a downturn, declining by approximately 3%. This marks the end of a five-month streak of gains. Similarly, the tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:QQQ), experienced a 3.5% decline. Among large-cap indices, blue-chip stocks showed slight underperformance, with the SPDR Dow Jones Industrial Average ETF (NYSE:DIA) slipping by 4.5%. Small-cap stocks, represented by the iShares Russell 200

Markets are primed for a revival in mergers and acquisitions (M&A) in 2024 following the worst performance in almost a decade for deal-making in 2023. Equity and M&A experts believe that, after a year beset by volatile markets and rising interest rates, 2024 offers improving conditions for takeover deals and corporate mergers. “Capital markets were not as open or freewheeling, and 2023 did not happen the way we thought it would," said Tom Miles, Head of Americas M&A at Morgan Stanley. “The market forces are in place that make an eventual return inevitable. It's not a question of if but when.” One piece of the M&A jigsaw that was largely missing last year was private equity (PE)

The early 2024 sell-off is intensifying on Wall Street, with all major stock averages in the red on the second trading day of 2024. The tech-heavy Nasdaq 100 plunged by 1% at noon in New York, extending its two-day slump to 2.6%. Wednesday’s declines spare no mercy for the blue-chip stocks of the Dow Jones, which managed to avoid losses on Tuesday, causing value-related stocks to fall as well. The S&P 500 index is at risk of closing its third consecutive day in the red, marking the worst streak since late October. Small-cap stocks, the stars of the late 2023 rally, are underperforming, with the iShares Russell 2000 ETF (NYSE:IWM) plummeting by 1.6%. The CBOE Volatility Index or VI

Wall Street kicked off 2024 on a weaker note, with the S&P 500 dipping by 0.5%, and the Nasdaq 100 experiencing a 1.4% decline in midday trading in New York. The tech sector played a notable role in dragging down the broader stock market performance. Interestingly, blue-chip and small-cap stocks managed to dodge substantial losses, showing marginal gains. Among the prominent “Magnificent Seven” stocks, six were in the red, with Tesla Inc. (NASDAQ:TSLA) being the sole exception, maintaining a flat performance for the day. Apple Inc. (NASDAQ:AAPL) took a notable hit, tumbling by 3%, marking its most challenging session since early September, following a downgrade from Barclays. NVIDIA Co

Piper Sandler Cos (NYSE:PIPR) has identified three biotech stocks as its “top picks” for 2024. The investment bank is signaling a potential turnaround for the sector next year. As illustrated in the data below, the biotech sector is lagging behind the broader U.S. equity market, as indicated by the performance of the SPDR S&P 500 ETF (NYSE:SPY).The iShares Biotechnology ETF (NYSE:IBB) is a popular benchmark to gauge the performance of biotech equities in the U.S. Also Read: Quality US Equities Lay Path To Gains In 2024: 3 ETFs To Consider As reported by CNBC, Piper Sandler analysts Edward Tenthoff and Thad Barney remain optimistic about the biotech industry. They see attractiv

The U.S. stock market saw modest gains in a session characterized by low trading volumes following the Christmas holiday. The S&P 500 Index gained 0.3% during midday trading in New York, eyeing its all-time highs, which are 1% above the current levels. Tech stocks within the Nasdaq 100 index experienced a slight uptick of 0.4%, while blue-chip stocks rose by 0.2%. Small-cap stocks, as represented by the iShares Russell 2000 ETF (NYSE:IWM), continued to outperform large-cap indices, extending the market narrative from December. The dollar saw a marginal 0.2% decrease, while Treasury yields remained stable. Gold recorded a 0.3% increase, reaching $2,060 per ounce, while Bitcoin (CRYPT

The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored inflation gauge in November, the Personal Consumption Expenditures (PCE) price index. For the S&P 500, this marks its longest run of positive weekly closes since September 2017, while for the Nasdaq 100, it’s the longest since January 2019. Additionally, economic data unveiled on Friday showed consumer spending to be softer than anticipated, along with a positive revision to the Michigan Consumer Sentiment Index and durable goods orders that surpassed expectations. The iShares Russell 2000

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ Biotechnology Index® (NASDAQ:NBI), effective December 19, 2022. The NASDAQ Biotechnology Index is designed to track the performance of a set of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market. Companies in the Index must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The Index is evaluat

WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today announced that NASDAQ has added the company to the NASDAQ Biotechnology Index® (NASDAQ:NBI) effective December 20, 2021. The NASDAQ Biotechnology Index is designed to track the performance of a set of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market® (Nasdaq®). Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other c

WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the company has been added to the NASDAQ Biotechnology Index® (NASDAQ:NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 20, 2021. The NASDAQ Biotechnology Index (NBI) is a modified market-cap weighted index designed to track the performance of a set of securities listed on the NASDAQ Stock Mark

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). Addition to the NBI will become effective prior to market open on Monday, December 20, 2021. The NASDAQ Biotechnology Index is designed to track the performance of a set of

LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI) and the iShares Biotechnology ETF (NYSE:IBB). The Nasdaq Biotechnology Index is a modified market capitalization-weighted index designed to track the performance of a set of qualifying NASDAQ-listed securities classified as either biotechnology or pharmaceuticals, according to the Industry Classifi

BlackRock, Inc. (NYSE:BLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup. No action is necessary for investors in the impacted ETFs and no capital gains distributions are currently expected as a result of the transition. iShares Nasdaq Biotechnology ETF (IBB) Effective on or around June 21, 2021, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) will seek to track the ICE Biotechnology Index. The fund will also undergo changes to its name and investment objective. Current New Fund Name iShares Nasdaq Biotechnology ETF iShares Biotechnology ETF Underlying Index Nasdaq Biotechnolo

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index (NBI) is a modified market-cap weighted index designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NBI is re-ranked each year

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index are listed on the NASDAQ Global

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). Addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmar

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NBI is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchm